INJECTABLE BONE GRAFT CONTAINING BONE MEDICATION AND BIOACTIVE GLASS.
A composition combining Denosumab with 45S5 bioactive glass in a polyethylene glycol carrier phase addresses the limitations of existing systems by inhibiting osteoclasts and promoting bone formation, offering improved fluidity and injectability for rapid bone repair.
Patent Information
- Application Number
- TR202509659
- Authority / Receiving Office
- TR · TR
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-07-14
- Publication Date
- 2026-10-21
AI Technical Summary
Existing injectable bone graft systems lack a composition that effectively inhibits osteoclast activity to prevent bone resorption while promoting bone formation and have inadequate fluidity and injectability for ease of application.
A composition combining controlled-release Denosumab with 45S5 bioactive glass in a carrier phase of polyethylene glycol and glycerol, providing pseudoplastic, thixotropic, and viscoelastic properties for injectability, and promoting apatite and calcite formation for rapid bone repair.
The composition effectively inhibits osteoclast activity, enhances bone formation, and improves fluidity and injectability, facilitating rapid bone repair by forming bone-like structures and suppressing bone resorption.
Abstract
Description
INJECTABLE BONE CONTAINING BONE MEDICINE AND BIOACTIVE GLASS GRAFTING Subject of the Invention The invention, 45S5, was developed for bone repair. as bioactive glass with 45S5 and polyethylene glycol (PEG) and Bone loss occurs within the carrier phase, which consists of glycerol. injectable containing the drug Denosumab, which is effective in its treatment This relates to a feasible bone graft composition. State of the Art In the field of biomaterials, particularly for bone repair. developed injectable systems, modern tissue It plays an important role in engineering. These systems are used in surgery. to reduce the need for intervention, to provide ease of implementation and is designed to speed up the healing process. Injectable bone grafts are generally biocompatible. carriers, osteoconductive materials such as bioactive glasses and sometimes biological agents that support cellular activity It includes these types of structures that promote bone tissue regeneration. promoting, dissolving in the body and being replaced by natural tissue. It stands out with its features that allow it to leave a mark. For the purpose of repairing and regenerating bone tissue. Existing injectable graft systems that have been developed, generally only carrier phase and bioactive glass It is based on a combination of these, and bone healing is different. Multifaceted impact that will provide support through biological mechanisms It falls short in terms of presentation. In particular, the bone. the activity of degrading cells (osteoclasts) with an effect aimed at preventing bone loss by suppressing it, a surface that simultaneously promotes the formation of bone-like structures 1 a composition that can provide all of these features The deficiency is noteworthy. Technique: Injectable bioactive for bone repair developments related to graft systems documents are available. US2023277545A1 is an example of the known state of the art. Patent document number [number] can be issued. This document concerns bone. For use in cases where homeostasis is disrupted. an improved composition exhibiting antiresorptive effects It is related to the composition in question, which affects osteoclast activity. It inhibits bone resorption and thus osteoporosis and Paget's disease, which are associated with bone loss. It aims to treat these conditions. Another example of the prior art is GB2590692A. Patent document number [number] can be issued. This document concerns orthopedic... Developed for use as a complementary treatment in surgery, in delayed fracture healing or bone fusion procedures applicable, containing parathyroid hormone (PTH) or its derivatives It relates to a composition. The composition refers to the topical application of PTH. By applying it in this way, it prolongs the lifespan of osteoblasts. While increasing the migration of mesenchymal stem cells to the fracture site, simultaneously suppressing osteoclast activity It prevents bone resorption with antiresorptive agents. Composition: calcium sulfate, bioactive glass, collagen sponge. or with carriers such as PMMA, during surgery prepared and administered via injection or in solid pellet form. It is structured in a practical way. Given the current state of the art, the carrier phase PEG and glycerol are used as alternatives to denosumab and 45S5. Synergistic effects resulting from the combined use of bioactive glass 2 a special composition formulated by taking advantage of the effect It is not encountered. Accordingly, controlled-release denosumab with 45S5 bioactive glass brought together within a carrier that provides, an effective injectable bone graft composition It has been developed. Detailed Description of the Invention The invention is an injectable form of Denosumab and bioactive glass. Development of bone graft compositions containing 45S5. It is related to. One aim of the invention is to inhibit osteoclast cells. Denosumab found in bioactive glasses by combining their features, bringing them together with a synergistic effect a composition that accelerates the ossification process by bringing to provide. Another aim of the invention is to improve fluidity and injectability. in a biocompatible carrier system with suitable availability a structure that supports both apatite and calcite formation to present. The invention is an injectable drug for bone tissue repair. is its composition, - A biocompatible carrier phase of 15–35%, - 50–80% 45S5 type bioactive glass particles and - Contains 1–15% Denosumab solution. In one configuration of the invention, the carrier phase in question is 30%– 40% polyethylene glycol 400, 5–20% polyethylene glycol 1500, 1–5% polyethylene glycol 3000 and 20–50% It contains glycerol in a certain percentage. 3 In another configuration of the invention, bioactive glass. particles larger than 100 µm, between 100–33 µm and above 33 µm They are small in size. In another configuration of the invention, the composition is fluid and It exhibits pseudoplastic, thixotropic, and viscoelastic properties. It is injectable and comes in a form requiring a 19G needle or larger diameter. The injectable bone graft composition is as follows: It is prepared in steps; - the amount required to obtain the desired end product polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 3000, glycerol, bioactive glass, and denosumab weighing the solution, - polyethylene glycol 400 and glycerol in liquid form Mixing at a temperature of 50–60 °C, - polyethylene glycol 1500 and polyethylene in solid form Adding glycol 3000 to the mixture in question, - solid bioactive glass particles of different sizes adding to the mixture – mixing all components homogeneously, - cooling the mixture, - Adding the denosumab solution to the cooled mixture, - homogenizing the mixture after the addition And - The final mixture is cooled again to obtain the final product. to be done. The composition of the invention has physical, chemical and functional characteristics. biocompatible, suitable for bone tissue repair in terms of its properties. and offers an injectable structure. The composition It is white or cream-colored, fluid, and weighs 19g or more. It is designed for injection with larger diameter needles. Flow behavior is pseudoplastic (showing shear thinning) or 4 It is of the Newtonian type, and easy to implement. It provides. It contains 45S5 type bioactive glass. It is in powder form, with particle sizes greater than 100 µm, 100– Different sizes between 33 µm and smaller than 33 µm. They are distributed in various sizes. The morphology of these glasses is irregular, Its crystal structure is amorphous. It comprises 50–80% by weight. Composition containing bioactive glass; high bioactivity, solubility and absorbability properties and cell migration It exhibits enhancing and antibacterial effects, as well as pseudoplastic, thixotropic, and viscoelastic flow behavior It is profitable. The carrier phase in the composition is 30–40% polyethylene. glycol 400, 5–20% polyethylene glycol 1500, 1–5% polyethylene glycol 3000 and 20–50% It consists of glycerol and is currently known to be biocompatible. It is one of the carriers. This carrier is used to store bioactive glass in bone. effective transport and placement in the defective area While providing the carrier, it dissolves and disappears over time. The composition is also used in the treatment of bone loss and osteoporosis. effective, osteoclast cell inhibiting, cellular Its activities are stimulating, fluid, and injectable. It contains denosumab, and thanks to this component, it only Not only is injection facilitated, but it also breaks down bone. bone destruction through suppression of cell activity bone formation is inhibited and supported at the cellular level. and the bioactivity of the composition is increased. In addition With the contribution of denosumab, only on the bioactive glass surface not only bone-like apatite structures, but also faster a soluble calcite layer also forms, and thus The ossification process is progressing more rapidly. The composition that is the subject of the invention, with existing technology compared in vitro bioactivity, calcite formation and It exhibits significant advantages in terms of fluidity. 28-day incubation in simulated body fluid (SBF). subsequently, in bone graft containing Denosumab and bioactive glass The proportion of crystalline bone-like structures formed on the surface is approximately While it is set at 30%, it only contains bioactive glass. In grafts, this rate is approximately 25%. This situation, The bioactivity-enhancing effect of denosumab supplementation was revealed. It includes samples that do not contain Denosumab. In comparison, the composition that is the subject of the invention has a glass surface It was observed that calcite formation occurred; this is also related to apatite. as well as contributing to the formation of a more rapidly soluble phase This has been achieved. In addition, the composition is suitable for cutting speeds of 100 s⁻¹. Having a viscosity below 1000 Pa·s and exhibiting pseudoplastic flow. Thanks to this feature, it is offered in injectable form. When all these features are considered together, the invention has both both biological efficacy and ease of application It provides significant advantages compared to existing solutions in technology. It is seen. One advantage of the invention is its ability to inhibit osteoclast cells. Its main feature is that it prevents bone destruction. Another advantage of the invention is its bioactive glass content. by promoting apatite and calcite formation on the surface, thus promoting ossification. It is about speeding things up. 6
Claims
1. An injectable drug for bone tissue repair. Its composition and characteristic are: - A biocompatible carrier phase at a concentration of 15–35%, - 50–80% 45S5 type bioactive glass particles and - Containing 1–15% Denosumab solution It is the characterization of the situation.
2. It is a composition according to Claim 1, and its characteristic is; carrier in phase, - 30–40% polyethylene glycol 400, - 5–20% polyethylene glycol 1500, - 1–5% polyethylene glycol 3000 and - Characterized by containing 20–50% glycerol. It is done.
3. It is a composition according to claim 1, and its characteristic is; bioactive. glass particles larger than 100 µm, between 100–33 µm and 33 It is characterized by having dimensions smaller than µm.
4. It is a composition according to claim 1, and its characteristic is that it is fluid and Exhibiting pseudoplastic, thixotropic and viscoelastic properties and it can be injected with a needle of 19G or larger diameter. It is the characterization of the situation.
5. An injectable bone graft composition It is a method for preparing [the product], and its characteristic feature is; - polyethylene glycol 400, polyethylene glycol 1500, polyethylene glycol 3000, glycerol, bioactive glass and Weighing the denosumab solution, - polyethylene glycol 400 in liquid form Mixing glycerol at a temperature of 50–60 °C, 7 - polyethylene glycol 1500 and in solid form polyethylene glycol 3000 in the mixture in question addition, - solid bioactive glass particles of different sizes adding to the mixture - homogeneous mixing of all components, - cooling the mixture, - Adding the denosumab solution to the cooled mixture, - the mixture becomes homogeneous again after the addition bringing and - obtained as the final product by cooling the final mixture again. It is characterized by including the steps involved in the process. It is done. 8
